8-K: Establishment Labs Announces Preliminary Q1 2025 Results and Investor Day

Establishment Labs expects preliminary Q1 2025 revenue of approximately $41.4 million and will host an investor day on June 12, 2025.

Summary

• Establishment Labs has released preliminary unaudited revenue figures for the first quarter of 2025.
• The company anticipates revenue of approximately $41.4 million, which includes about $6.2 million from Motiva sales in the United States.
• An investor day is scheduled for June 12, 2025, in New York City, where the leadership team will provide updates on the Motiva launch in the U.S., the innovation roadmap, and the financial outlook.
• The company reaffirms its previous revenue guidance of $205 to $210 million for 2025.
• Tariffs are expected to have a minimal impact, less than a 50-basis point gross margin impact.
• Establishment Labs still expects to achieve EBITDA positivity in 2025 and cash flow positivity in 2026.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strong Q1 performance, successful U.S. launch, reaffirmed guidance, and the expectation of achieving profitability milestones. However, the forward-looking statements disclaimer tempers the enthusiasm slightly.

Positives

• The company's U.S. launch is accelerating, with average orders in March surpassing 100 per day.
• Establishment Labs reaffirms its revenue guidance for 2025.
• The company is on track to achieve EBITDA positivity in 2025 and cash flow positivity in 2026.
• Tariffs are expected to have a minimal impact on gross margin.

Risks

• The preliminary financial results are forward-looking statements and may differ materially from actual results.
• The company operates in a competitive and rapidly changing environment, with new risk factors emerging from time to time.
• The company's actual future results and the timing of events may differ from its expectations, and those differences may be material.

Future Outlook

Establishment Labs reaffirms its revenue guidance of $205 to $210 million for 2025 and expects to achieve EBITDA positivity in 2025 and cash flow positivity in 2026.

Management Comments

• The second quarter appears strong, and the United States launch continues to accelerate said Peter Caldini, Establishment Labs Interim CEO.
• Average orders in March surpassed 100 per day, and we expect this growth to continue, making our launch one of the fastest in aesthetic history.
• We have not seen any disruption to our business from recent events and affirm our previous commentary and guidance on revenue of $205 to $210 million for 2025.

Industry Context

Establishment Labs is operating in the global medical device industry, specifically within breast aesthetics and reconstruction. The announcement highlights the company's focus on innovation and expansion in the U.S. market, which is a key growth area for medical device companies.

Comparison to Industry Standards

• Establishment Labs competes with companies like Allergan (now part of AbbVie), Mentor (owned by Johnson & Johnson), and Sientra in the breast implant market.
• The company's claim of one of the fastest launches in aesthetic history suggests they are outperforming typical market adoption rates for new products in this sector.
• Achieving EBITDA positivity in 2025 and cash flow positivity in 2026 would be a significant milestone, as many smaller medical device companies struggle to reach profitability quickly.

Stakeholder Impact

• Shareholders can expect updates on the company's performance and strategy at the investor day.
• Customers (plastic surgeons and patients) will benefit from the continued innovation and expansion of the Motiva product line.
• Employees can anticipate growth opportunities as the company expands its operations.

Next Steps

• The company will host an investor day on June 12, 2025, to provide further updates.
• The company will continue to focus on the U.S. launch of Motiva and the development of its product pipeline.

Key Dates

Keywords

Establishment Labs, Motiva, revenue, Q1 2025, investor day, breast aesthetics, breast reconstruction, medical technology